PEPTIDE FOR VACCINE
The present invention relates to compositions comprising peptides for preventing or treating allergy to house dust mites, and in particular to optimal combinations of peptides for preventing or treating said allergy.
1 . A polypeptide consisting of:
(i) a sequence selected from any one of SEQ ID NOs: 1 to 104; or
(ii) the sequence of SEQ ID NO: 101 in which the N terminal glutamate (E) is replaced with pyroglutamate;
or a variant of said polypeptide which is 9 to 30 amino acids in length and comprises:
the said sequence of (i) or (ii); or
a sequence which has at least 80% identity to the said sequence of (i) or (ii); or
a sequence which has one, two or three conservative amino acid substitutions relative to the said sequence of (i) or (ii); or
a fragment of the said sequence of (i) or (ii) which is at least nine amino acids in length.
2 . The polypeptide or variant thereof according to claim 1 wherein the sequence is selected from the group consisting of SEQ ID NOs: 65, 63, 73, 80, 83 and 85.
3 . A composition comprising at least one polypeptide or variant thereof as defined in claim 1 ; and at least one pharmaceutically acceptable diluent or carrier.
4 . A composition comprising at least one pharmaceutically acceptable diluent or carrier and:
(i) a polypeptide consisting of the sequence of SEQ ID NO: 65, or a variant of said polypeptide as defined in claim 1 ;
(ii) a polypeptide consisting of the sequence of SEQ ID NO: 63, or a variant of said polypeptide as defined in claim 1 ;
(iii) a polypeptide consisting of the sequence of SEQ ID NO: 73, or a variant of said polypeptide as defined in claim 1 ;
(iv) a polypeptide consisting of the sequence of SEQ ID NO: 80, or a variant of said polypeptide as defined in claim 1 ;
(v) a polypeptide consisting of the sequence of SEQ ID NO: 83, or a variant of said polypeptide as defined in claim 1 ;
(vi) a polypeptide consisting of the sequence of SEQ ID NO: 85, or a variant of said polypeptide as defined in claim 1 ; and
(vii) a polypeptide consisting of the sequence of SEQ ID NO: 101 in which the N terminal glutamate (E) is replaced with pyroglutamate, or a variant of said polypeptide as defined in claim 1 .
5 . The composition according to claim 3 , which is a solution in which each said polypeptide or variant is present at a concentration in the range of 0.03 to 200 nmol/ml, 0.3 to 200 nmol/ml or 30 to 120 nmol/ml.
6 . The composition according to claim 4 , which is a solution in which each said polypeptide or variant is present at a concentration in the range of 0.03 to 200 nmol/ml, 0.3 to 200 nmol/ml or 30 to 120 nmol/ml.
7 . The composition according to claim 3 , which is formulated for oral administration, nasal administration, epicutaneous administration, subcutaneous administration, sublingual administration, intradermal administration, buccal administration or for administration by inhalation or by injection.
8 . The composition according to claim 4 , which is formulated for oral administration, nasal administration, epicutaneous administration, subcutaneous administration, sublingual administration, intradermal administration, buccal administration or for administration by inhalation or by injection.
9 . A method of treating allergy to house dust mite, comprising administering to an individual a therapeutically effective amount of a composition according to claim 3 .
10 . A method of treating allergy to house dust mite, comprising administering to an individual a therapeutically effective amount of a composition according to claim 4 .